TuHURA Biosciences, Inc. borrowed $650,000 on August 20, 2026, under a revolving credit facility established with Parkview Holdings One LLC in April 2026. The loan agreement provides for a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.

TuHURA Biosciences held its 2026 Annual Meeting on August 18, 2026. Stockholders approved the issuance of 1,878,287 shares of common stock to Parkview Holdings One LLC as a loan fee under a $50 million revolving credit facility entered into in April 2026. The company also elected six directors: James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler. Shareholders ratified the advisory vote on executive compensation, selected a three-year frequency for future say-on-pay votes, and reappointed Cherry Bekaert LLP as independent auditor. These are routine governance actions without material financial impact. TuHURA Biosciences operates in the biotechnology industry, focusing on drug discovery.

TuHURA Biosciences reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company filed an Investigational New Drug (IND) application for TBS-2025 in Acute Myeloid Leukemia (AML). TuHURA has received $5.7 million to date on its Parkview credit facility, which includes $2.15 million subsequent to June 30, 2026. Cash and cash equivalents were $1.0 million at quarter-end. Research and development expenses increased to $6.6 million from $4.9 million in the prior year period. The company anticipates receiving safe-to-proceed feedback from the FDA and initiating Phase 1b/2 trials for VISTA in AML during the second half of 2026. TuHURA Biosciences is a biopharmaceutical company developing immuno-oncology therapeutics to overcome resistance to cancer immunotherapy.

TuHURA Biosciences, Inc. borrowed an additional $1,500,000 under its existing revolving credit facility with Parkview Holdings One LLC on July 28, 2026. The loan agreement, originally entered into on April 21, 2026, provides a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates in the biotechnology industry, focusing on drug discovery and development.

TuHURA Biosciences, Inc. drew $1,900,000 from its existing $50 million revolving credit facility with Parkview Holdings One LLC on June 30, 2026. The funds are intended for general corporate purposes. The revolving credit facility, originally established on April 21, 2026, is scheduled to mature on April 21, 2031. TuHURA Biosciences is a biotechnology company.